Cargando…

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group

Multiple myeloma (MM) is an incurable disease and patients become refractory to the treatment in the course of the disease. Bendamustine-based regimens containing steroids and other agents are among the therapeutic options offered to MM patients. Here, we investigated the safety and the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grzasko, Norbert, Charlinski, Grzegorz, Morawska, Marta, Kicinski, Pawel, Waszczuk-Gajda, Anna, Drozd-Sokolowska, Joanna, Subocz, Edyta, Blonska, Danuta, Razny, Malgorzata, Druzd-Sitek, Agnieszka, Holojda, Jadwiga, Swiderska, Alina, Usnarska-Zubkiewicz, Lidia, Masternak, Anna, Giannopoulos, Krzysztof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658377/ https://www.ncbi.nlm.nih.gov/pubmed/34884206 http://dx.doi.org/10.3390/jcm10235504

Ejemplares similares

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group
por: Hus, Iwona, et al.
Publicado: (2019)

A Stepwise Screening Protocol for Multiple Myeloma
por: Morawska, Marta, et al.
Publicado: (2023)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma
por: Bartosińska, Joanna, et al.
Publicado: (2021)

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy
por: Dytfeld, Dominik, et al.
Publicado: (2016)

Atypical chronic myeloid leukaemia – a rare subtype of myelodysplastic/myeloproliferative neoplasm
por: Drozd-Sokołowska, Joanna E., et al.
Publicado: (2018)

Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia
por: Masternak, Marta, et al.
Publicado: (2020)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis
por: Debski, Jakub, et al.
Publicado: (2018)

The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age
por: Tyczyńska, Agata, et al.
Publicado: (2023)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

P980: THE ROLE OF PLATELET AND ENDOTHELIAL MICROPARTICLES AND DOPPLER ULTRASOUND SCREENING IN THE ASSESSMENT OF THROMBOTIC READINESS IN MULTIPLE MYELOMA AND NON HODGKIN LYMPHOMA, PROSPECTIVE STUDY
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2023)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
por: Cerchione, Claudio, et al.
Publicado: (2016)

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
por: Avivi, Irit, et al.
Publicado: (2023)

Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients
por: Kulikowska de Nałęcz, Anna, et al.
Publicado: (2021)

Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors
por: Kulikowska de Nałęcz, Anna, et al.
Publicado: (2023)

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

A polygenic risk score for multiple myeloma risk prediction
por: Canzian, Federico, et al.
Publicado: (2021)

Epidemiology of multiple myeloma in Poland in the years 2008–2017
por: Waszczuk-Gajda, Anna, et al.
Publicado: (2020)

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
por: Cerchione, Claudio, et al.
Publicado: (2017)

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2021)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

State of Oral Mucosa as an Additional Symptom in the Course of Primary Amyloidosis and Multiple Myeloma Disease
por: Czerniuk, Maciej R., et al.
Publicado: (2014)

New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies
por: Woziwodzka, Karolina, et al.
Publicado: (2020)

Genetically determined telomere length and multiple myeloma risk and outcome
por: Giaccherini, Matteo, et al.
Publicado: (2021)

Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland – a report of the Polish Lymphoma Research Group
por: Kalinka, Ewa, et al.
Publicado: (2019)

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma
por: Issa, Issa Ismail, et al.
Publicado: (2021)

P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
por: Yuping, Z., et al.
Publicado: (2022)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
por: Charliński, Grzegorz, et al.
Publicado: (2021)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
por: Ramasamy, Karthik, et al.
Publicado: (2022)

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
por: Hus, Marek, et al.
Publicado: (2011)

A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
por: Dicanio, Marco, et al.
Publicado: (2022)

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
por: Cerchione, Claudio, et al.
Publicado: (2016)

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
por: Leng, Siyang, et al.
Publicado: (2020)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
por: Offidani, M, et al.
Publicado: (2013)

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
por: Green, Damian J., et al.
Publicado: (2016)

P1439: IMMUNE RESPONSE TO ANTI-SARS-COV-2 MRNA VACCINES IN MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Zaleska, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7sb0ks0qh2nfd1l0bvqkm6scvs